NovaBone Products launched NovaBone IRM and NovaBone IRM MacroPOR to its portfolio of biologically-active bone graft substitutes.
Both formulations are designed to optimize osteogenesis, stimulate osteoblastic activity and offer angiogenic potential. The products are highly resistant to irrigation and designed with high-performing cohesion and handling properties.
Novabone’s portfolio of bioactive synthetic bone graft subs include minimally invasive delivery devices such as the MacroFORM MIS ready-to-use cannula and strip/ready-to-use putty formulations.
Sources: NovaBone Products; ORTHOWORLD Inc.
NovaBone Products launched NovaBone IRM and NovaBone IRM MacroPOR to its portfolio of biologically-active bone graft substitutes.
Both formulations are designed to optimize osteogenesis, stimulate osteoblastic activity and offer angiogenic potential. The products are highly resistant to irrigation and designed with high-performing cohesion and...
NovaBone Products launched NovaBone IRM and NovaBone IRM MacroPOR to its portfolio of biologically-active bone graft substitutes.
Both formulations are designed to optimize osteogenesis, stimulate osteoblastic activity and offer angiogenic potential. The products are highly resistant to irrigation and designed with high-performing cohesion and handling properties.
Novabone’s portfolio of bioactive synthetic bone graft subs include minimally invasive delivery devices such as the MacroFORM MIS ready-to-use cannula and strip/ready-to-use putty formulations.
Sources: NovaBone Products; ORTHOWORLD Inc.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.